Science

Articles

• Vect-Horus and its academic partners describe the chemical optimisation of one of its lead peptides (Malcor et al., 2012, J Med Chem)
  28 January 2019, by Jonathan NOWAK

  and publish a review article on CNS drug delivery (Vlieghe and Khrestchatisky, 2012, Med Res Rev).

• LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma
  30 September 2021, by Elodie DORMES

  Vect-Horus is proud to be part of the research in PDAC with its theranostic agents to first improve PDAC diagnosis, response monitoring or recurrence detection in operated patients and also treat them.
  Cedric malicet, Oncology Department Manager, is pleased to inform you of the recent publication of the article “ LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma “ in Communications Biology.

• NTSR2 is induced in astrocytes and brain endothelial cells in relation to neuroinflammation following pilocarpine-induced seizures in rats
  30 September 2021, by Elodie DORMES

  Neurotensin (NT) acts as a primary neurotransmitter and neuromodulator in the CNS and has been involved in a number of CNS pathologies including epilepsy. NT mediates its central and peripheral effects by interacting with the NTSR1, NTSR2, and Sort1/NTSR3 receptor subtypes. To date, little is known about the precise expression of the NT receptors in brain neural cells and their regulation in pathology. In the present work, we studied the cellular distribution of the NTSR2 protein in the rat (…)

• Vect-Horus focuses on Target engagement and intracellular delivery of LDLR conjugates to design new targeted drug therapies
  27 November 2019, by Elodie DORMES

  Varini et al. J Control Release 2019
  Targeted delivery to specific tissues and subcellular compartments is of paramount importance to optimize therapeutic or diagnostic interventions while minimizing side-effects. Using recently identified LDL receptor (LDLR) -targeting small synthetic peptide-vectors conjugated to model cargos of different nature and size, we investigated in LDLR-expressing cells the impact of vector-cargo molecular engineering and coupling valency, as well as the (…)

• Two research groups specialized in CNS drug delivery and in the development of therapeutic strategies for glioblastoma give in vivo POC on one of the peptide vectors described by Vect-Horus
  28 January 2019, by Jonathan NOWAK

  Two groups of the Institute of Hematology, Huazhong University in Wuhan and the Key Laboratory of Smart Drug Delivery, Fudan University in Shanghai, well known and specialized in CNS drug delivery and in the development of therapeutic strategies for glioblastoma, show evidence in mice (Zhang et al., 2013, Biomaterials) of nanoparticle targeting to the brain and glioblastoma with therapeutic benefit, with one of the peptide vectors described by VECT-HORUS in Malcor et al. (2012, J Med Chem).